The true measurement here is both scientific and f
Post# of 72445
(Total Views: 191)
Posted On: 08/28/2018 11:24:18 AM
The true measurement here is both scientific and fiscal responsibility.
Yes the science has progressed. The possibility has always been there for big pharma to step in and say "I want this now" for either of the pipeline drugs at virtually any point. The fiscal part is deciding where to stop before major dilution would be required to "go it alone". And yes, we've seen companies dilute like crazy to attempt to move forward on their own only to get raked over the coals into oblivion. Leo has controlled this very well imo. Think Leo was telling BP, "But wait! There's more!"? That's where we are now waiting on P data before the partnership imo. The recent raises were needed. Could they have been better? We'll, if I was an insider I could answer that need. So now we have 4 pipeline products, almost a 5th, at the starting gates for their next trials. UP, OM, ABBBSI, Kevetrin and almost Prurisol. Not to mention the dermatology potential.
There are many ways someone can say Leo has done the right thing or wrong thing. Not moving products forward that patients needed yesterday is certainly one argument. But I suggest, starting something without the means of making it to the end (as I've seen PLENTY of companies drop dead trying) is even more detrimental.
So I'm onboard with the patience to see Leo's plan come to fruition.
Yes the science has progressed. The possibility has always been there for big pharma to step in and say "I want this now" for either of the pipeline drugs at virtually any point. The fiscal part is deciding where to stop before major dilution would be required to "go it alone". And yes, we've seen companies dilute like crazy to attempt to move forward on their own only to get raked over the coals into oblivion. Leo has controlled this very well imo. Think Leo was telling BP, "But wait! There's more!"? That's where we are now waiting on P data before the partnership imo. The recent raises were needed. Could they have been better? We'll, if I was an insider I could answer that need. So now we have 4 pipeline products, almost a 5th, at the starting gates for their next trials. UP, OM, ABBBSI, Kevetrin and almost Prurisol. Not to mention the dermatology potential.
There are many ways someone can say Leo has done the right thing or wrong thing. Not moving products forward that patients needed yesterday is certainly one argument. But I suggest, starting something without the means of making it to the end (as I've seen PLENTY of companies drop dead trying) is even more detrimental.
So I'm onboard with the patience to see Leo's plan come to fruition.
(7)
(0)